Comparison of The Effects of Methylphenidate Plus Betahistine and Methylphenidate Plus Placebo on Attention Deficit Hyperactivity Disorder in Children
Background: Attention deficit hyperactivity disorder (ADHD) is a common disorder during childhood that leads to impairment in functioning in academic and career domains and social responsibility. Methylphenidate is a common treatment for ADHD that may not be taken by patients due to its complications. The goal of the present study is to examine and compare the effects of Methylphenidate plus Betahistine and Methylphenidate plus placebo on ADHD in Children.
Methods: This was a randomized double-blind clinical trial with control group conducted with 76 children with ADHD referred to Be’sat Hospital in Sanandaj, Iran in 2019. The data was collected using the demographic form, a researcher-made form for assessing the reported complications of Methylphenidate and Betahistine, ADHD Rating Scale and the Clinical Global Impression – Severity scale (CGI-S).
Results: There was no age difference between the two experimental groups. Both groups experienced a reduction in intensity of ADHD symptoms according to mean scores, but there was more reduction in the Methylphenidate plus Betahistine than the other group. The most common complications in the two groups were lack of appetite (weeks 2 and 4) and agitation and vertigo (week 2).
Conclusion: Betahistine plus Methylphenidate may be more effective in treating ADHD symptoms compared to Methylphenidate alone.
Figure 1
Posted 13 Jan, 2021
On 07 Jan, 2021
On 07 Jan, 2021
On 07 Jan, 2021
On 07 Jan, 2021
Comparison of The Effects of Methylphenidate Plus Betahistine and Methylphenidate Plus Placebo on Attention Deficit Hyperactivity Disorder in Children
Posted 13 Jan, 2021
On 07 Jan, 2021
On 07 Jan, 2021
On 07 Jan, 2021
On 07 Jan, 2021
Background: Attention deficit hyperactivity disorder (ADHD) is a common disorder during childhood that leads to impairment in functioning in academic and career domains and social responsibility. Methylphenidate is a common treatment for ADHD that may not be taken by patients due to its complications. The goal of the present study is to examine and compare the effects of Methylphenidate plus Betahistine and Methylphenidate plus placebo on ADHD in Children.
Methods: This was a randomized double-blind clinical trial with control group conducted with 76 children with ADHD referred to Be’sat Hospital in Sanandaj, Iran in 2019. The data was collected using the demographic form, a researcher-made form for assessing the reported complications of Methylphenidate and Betahistine, ADHD Rating Scale and the Clinical Global Impression – Severity scale (CGI-S).
Results: There was no age difference between the two experimental groups. Both groups experienced a reduction in intensity of ADHD symptoms according to mean scores, but there was more reduction in the Methylphenidate plus Betahistine than the other group. The most common complications in the two groups were lack of appetite (weeks 2 and 4) and agitation and vertigo (week 2).
Conclusion: Betahistine plus Methylphenidate may be more effective in treating ADHD symptoms compared to Methylphenidate alone.
Figure 1